European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care
BEERSE, BELGIUM, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced that the European Commission (EC) has approved an indication extension for TECVAYLI ® (teclistamab) in combination with daratumumab for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at le…
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- LA Limited Addition Drumline, Breast Cancer Prevention Advocates Join Actress Dionne Lea and Renowned Breast Cancer Surgeon Dr. Kristi Funk to Rally in View Park to “Beat” Breast Cancer
- Audrey Saylor Scholarship for Manufacturing Announces One-Time Award to Support Future Industry Leaders in South Dakota and Beyond
- Michael Wiese Announces South Dakota-Based Engineering Scholarship to Support National Undergraduate Talent
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →